tiprankstipranks
Trending News
More News >
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX

Pacira Pharmaceuticals (PCRX) Stock Statistics & Valuation Metrics

Compare
367 Followers

Total Valuation

Pacira Pharmaceuticals has a market cap or net worth of $1.09B. The enterprise value is $2.15B.
Market Cap$1.09B
Enterprise Value$2.15B

Share Statistics

Pacira Pharmaceuticals has 46,304,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,304,670
Owned by Insiders2.69%
Owned by Institutions22.04%

Financial Efficiency

Pacira Pharmaceuticals’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -7.96%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-7.96%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee889.55K
Profits Per Employee-126.35K
Employee Count788
Asset Turnover0.45
Inventory Turnover1.36

Valuation Ratios

The current PE Ratio of Pacira Pharmaceuticals is -8.75. Pacira Pharmaceuticals’s PEG ratio is 0.23.
PE Ratio-8.75
PS Ratio0.00
PB Ratio1.79
Price to Fair Value1.12
Price to FCF11.18
Price to Operating Cash Flow10.08
PEG Ratio0.23

Income Statement

In the last 12 months, Pacira Pharmaceuticals had revenue of 700.97M and earned -99.56M in profits. Earnings per share was -2.15.
Revenue700.97M
Gross Profit530.54M
Operating Income-73.37M
Pretax Income-63.11M
Net Income-99.56M
EBITDA32.25M
Earnings Per Share (EPS)-2.15

Cash Flow

In the last 12 months, operating cash flow was 175.75M and capital expenditures -16.35M, giving a free cash flow of 159.40M billion.
Operating Cash Flow175.75M
Free Cash Flow159.40M
Free Cash Flow per Share3.44

Dividends & Yields

Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.78
52-Week Price Change-17.50%
50-Day Moving Average25.39
200-Day Moving Average21.55
Relative Strength Index (RSI)35.08
Average Volume (3m)584.04K

Important Dates

Pacira Pharmaceuticals upcoming earnings date is Aug 5, 2025, Before Open (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend Date

Financial Position

Pacira Pharmaceuticals as a current ratio of 2.40, with Debt / Equity ratio of 67.35%
Current Ratio2.40
Quick Ratio2.00
Debt to Market Cap0.67
Net Debt to EBITDA11.23
Interest Coverage Ratio-4.43

Taxes

In the past 12 months, Pacira Pharmaceuticals has paid 36.45M in taxes.
Income Tax36.45M
Effective Tax Rate-0.58

Enterprise Valuation

Pacira Pharmaceuticals EV to EBITDA ratio is 38.25, with an EV/FCF ratio of 6.90.
EV to Sales1.76
EV to EBITDA38.25
EV to Free Cash Flow6.90
EV to Operating Cash Flow6.51

Balance Sheet

Pacira Pharmaceuticals has $493.63M in cash and marketable securities with $636.46M in debt, giving a net cash position of $142.83M billion.
Cash & Marketable Securities$493.63M
Total Debt$636.46M
Net Cash$142.83M
Net Cash Per Share$3.08
Tangible Book Value Per Share$7.62

Margins

Gross margin is 72.64%, with operating margin of -10.47%, and net profit margin of -14.20%.
Gross Margin72.64%
Operating Margin-10.47%
Pretax Margin-9.00%
Net Profit Margin-14.20%
EBITDA Margin4.60%
EBIT Margin-7.09%

Analyst Forecast

The average price target for Pacira Pharmaceuticals is $41.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$41.25
Price Target Upside75.68% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast3.08%
EPS Growth Forecast-247.82%

Scores

Smart Score2
AI Score59
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis